Ramaswamy Govindan, MD, professor of medicine, Washington University School of Medicine discusses the results of a phase I study looking at safety, tolerability, pharmacokinetics (PK), and efficacy of KRAS G12C inhibitor, AMG 510 in patients with non—small cell lung cancer. (NSCLC).

 G12C mutation and adenocarcinoma, says Govindan. More than 85% of them had more than two prior lines of therapy, making this a typical group of patients with NSCLC. However, the findings thus far have not been typical.

AMG 510 was found to be well tolerated and showed antitumor activity. The investigators hope to see similar trends regarding safety, PK, and efficacy when more data becomes available.

Videos

Ramaswamy Govindan, MD, professor of medicine, Washington University School of Medicine discusses the results of a phase I study looking at safety, tolerability, pharmacokinetics, and efficacy of KRAS G12C inhibitor, AMG 510 in patients with non-small cell lung cancer.

Dr. Govindan on the Phase I Results of AMG 510 Evaluated in NSCLC

Ramaswamy Govindan, MD, medical oncologist, Siteman Cancer Center and Washington University School of Medicine in St. Louis, discusses a talk given at the 16th World Conference on Lung Cancer.

Govindan says he was struck by the fact that some samples of large-cell neuroendocrine lung tumors look like small cell lung cancer while others look like non-small cell lung cancer (NSCLC). These tumors typically present in smokers and lead to poor outcomes.

There remains a need, he says, to understand the biology of these cancers so they can be treated with biological and rational therapies.

View more from the 2015 World Conference on Lung Cancer

Ramaswamy Govindan, MD, medical oncologist, Washington University School of Medicine in St. Louis, discusses a talk given at the 16th World Conference on Lung Cancer.

Dr. Govindan on the Genomic Characterization of Large-Cell Neuroendocrine Lung Tumors

Ramaswamy Govindan, MD, Director, Thoracic Oncology, Co-Director, Section of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the potential for the ALK inhibitor alectinib.

Crizotinib and ceritinib are approved in the US and have demonstated 50-60% response rates in patients with ALK-positive non-small cell lung cancer (NSCLC). In a small study in Japan, alectinib elicited a 93% response rate, median survival of 27 months, and activity against brain metastases. Studies in the US are being conducted now comparing crizotinib and alectinib.

There remains a need to understand resistance, and mechanisms of resistance, of these 3 agents. The question also remains as to whether ALK-positive patients should be stratified.

View more from the 2014 Multidisciplinary Symposium in Thoracic Oncology

Ramaswamy Govindan, MD

Articles

Dr. Govindan on the Phase I Results of AMG 510 Evaluated in NSCLC

Dr. Govindan on the Genomic Characterization of Large-Cell Neuroendocrine Lung Tumors

Dr. Govindan on the Potential for Alectinib